Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Memory boost for cocaine users? small study tests potassium channel blocker

NCT ID NCT07532460

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 18, 2026 · Updated 2 times

Summary

This study looks at whether a drug called fampridine, which blocks potassium channels in the brain, can improve working memory in people with cocaine use disorder. Forty chronic cocaine users will receive either the drug or a placebo and then take memory tests. The goal is to understand the brain mechanisms behind cognitive problems in cocaine users, not to test a cure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
fampridine (4-aminopyridine)
What this could lead to
If it works, this could point toward a treatment for cognitive impairments in people with cocaine use disorder.
What could go wrong
This is a very small, early-stage study with only 40 participants. It tests a single dose, so any effects may be temporary or not translate to real-world benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 50 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Current diagnosis of mild, moderate, or severe CoUD according to DSM-5 * Minimum cocaine use of 1g/month in the last three months * Cocaine as the primary drug of consumption * Willingness to abstain from cocaine use at least 72 hours before prior to each study visit * Ability to read, understand and provide written informed consent * To be sufficiently fluent in German * Age between 20 and 50 years * Body mass index (BMI) between 19 and 30 kg/m2 * If applicable: luteal phase of the menstrual cycle * For individuals with childbearing potential: use of contraceptive measures Exclusion Criteria: * Presence or history of severe neurological disorders or head injuries * Current diagnosis of an acute or chronic infectious disease * If applicable: pregnancy and breastfeeding * Lifetime history of any epileptic seizures * Lifetime diagnosis of a cardiovascular disease, specifically arrhythmia and long QT syndrome * Clinically significant laboratory or ECG abnormality that could be a safety issue in the study * Lifetime diagnosis of liver or kidney disease including moderate or severe renal impairment (creatinine clearance \< 50 ml/min) * Known hypersensitivity or allergy to 4-aminopyridine * Use of potassium channel blockers within the last 3 months * Use of psychotropic medication within the last 7 days * Use of inhibitors of the organic cation transporter 2 (OCT2), such as cimetidine * Lifetime diagnosis of schizophrenia, bipolar disorder, obsessive-compulsive disorder, or autism spectrum disorder according to DSM-5 * Diagnosis of a current episode of depression * Current diagnosis of a moderate or severe substance use disorder other than CoUD according than DSM-5 * Daily cannabis consumption in the past three months * (E-Cigarette) Fagerström Test of Nicotine Dependence Score \> 5 (strong nicotine dependence) * Inability to follow the procedures of the study, e.g., due to language problems * Being related to or in any form dependent on the investigator * Prior participation (less than two years ago) in a study investigating working memory using the n-back task, the SWM, PAL, RVP, or LNST * Participation in another study with investigational drugs within the 30 days preceding and during the present study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cocaine use disorder (CUD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Hospital of Psychiatry Zurich

    RECRUITING

    Zurich, Canton of Zurich, 8008, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.